Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis

Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis

Item
http://www.wikidata.org/entity/Q36336024
Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese populationThe effects of Vitamin C on sperm quality parameters in laboratory rats following long-term exposure to cyclophosphamide.A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis.Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response.Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceCD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.Optimizing the use of existing therapies in lupus.The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy.Renal Drug Transporters and Drug Interactions.Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study.Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis.Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma
P2860

Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis

Item
http://www.wikidata.org/entity/Q36336024
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cyclophosphamide and 4-hydroxy ...... us and small vessel vasculitis
@ast
Cyclophosphamide and 4-hydroxy ...... us and small vessel vasculitis
@en
type
label
Cyclophosphamide and 4-hydroxy ...... us and small vessel vasculitis
@ast
Cyclophosphamide and 4-hydroxy ...... us and small vessel vasculitis
@en
prefLabel
Cyclophosphamide and 4-hydroxy ...... us and small vessel vasculitis
@ast
Cyclophosphamide and 4-hydroxy ...... us and small vessel vasculitis
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Cyclophosphamide and 4-hydroxy ...... us and small vessel vasculitis
@en
P2093
P2860
P304
P31
P356
10.1111/J.1365-2125.2012.04223.X
P407
P433
P478
P577
P5875
P698
P921
P932